We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Exploiting Cancer Cell Vulnerabilities To Create More Effective Cancer Therapies
News

Exploiting Cancer Cell Vulnerabilities To Create More Effective Cancer Therapies

Exploiting Cancer Cell Vulnerabilities To Create More Effective Cancer Therapies
News

Exploiting Cancer Cell Vulnerabilities To Create More Effective Cancer Therapies

This image depicts the APOBEC3A protein (yellow) attacking a DNA hairpin (white) to promote the deamination of the cytosine (bright orange) generating DNA mutations in the genome of the cancer cell. Credit: UCI School of Medicine
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Exploiting Cancer Cell Vulnerabilities To Create More Effective Cancer Therapies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

The study, published today in Nature Communications, titled, “Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots,” reveals how the genomic instability induced by the protein APOBEC3A offers a previously unknown vulnerability in cancer cells.

Each day, in human cells, tens of thousands of DNA damage events occur.  In cancer cells, the expression of the protein APOBEC3A is one of the most common sources of DNA damage and mutations.  While the mutations caused by these particular proteins in cancer cells contribute to tumor evolution, they also cause breaks in the DNA, which offer a vulnerability.

“Targeting cancer cells with high levels of APOBEC3A protein activities and disrupting, at the same time, the DNA damage response necessary to repair damages caused by APOBEC3A, could be key to more effective cancer therapies,” said Remi Buisson, PhD, senior investigator and an assistant professor in the Department of Biological Chemistry at the UCI School of Medicine.  “However, to exploit the vulnerability of the cancer cells, it is critical to first quantitatively measure the protein’s activity in tumors.”

To understand the role of APOBEC3A in tumor evolution and to target the APOBEC3A -induced vulnerabilities, the researchers developed an assay to measure the RNA-editing activity of APOBEC3A in cancer cells.  Because APOBEC3A is difficult to quantify in tumors, developing a highly sensitive assay for measuring activity was critical.  Using hotspot RNA mutations, identified from APOBEC3A-positive tumors, the team developed an assay using droplet digital PCR and demonstrated its applicability to clinical samples from cancer patients.

“Our study presents a new strategy to follow the dysregulation of APOBEC3A in tumors, providing opportunities to investigate the role of APOBEC3A in tumor evolution and to target the APOBEC3A-induced vulnerability in therapy,” said Buisson. “We anticipate that the RNA mutation-based APOBEC3A assay will significantly advance our understanding of the function of the protein in tumorigenesis and allow us to more effectively exploit the vulnerabilities it creates in cancer therapy.”

This study was funded in part by the National Institutes of Health, a California Breast Cancer Research Program grant and an MPN Research Foundation Challenge grant.

Reference: Jalili, P., Bowen, D., Langenbucher, A. et al. (2020) Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots. Nat Commun. DOI: https://doi.org/10.1038/s41467-020-16802-8

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement